Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. There has been a rapid increase in the overall healthcare expenditure, globally, over the past few years. Therefore, there are new medical technologies, treatments, and medicines available for bladder cancer diseases that contribute majorly to the overall rise in healthcare costs. The high drug prices, drug patent expiry, and cost of healthcare services account for the two-third increase in healthcare spending. The expenditure on increased services, which includes costs of labor and productivity (in biopharmaceutical industries), is also one of the major factors driving healthcare costs.

In addition, the growing research in the development of innovative bladder cancer therapies and the availability of pipeline therapeutics are further propelling the growth of the bladder cancer therapeutics market. Furthermore, the rise in awareness about bladder cancer and its available therapies and the growing smoking and tobacco consumption are also driving the market.

Key Market Trends

Cystoscopy is Anticipated to be the Dominant Segment in Diagnostics over the Forecast Period

Cystoscopy is a procedure used to observe the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is cost-effective. However, in combination with other tests, its cost can vary. There are approximately 1.2 million flexible cystoscopy procedures conducted annually in the United States. Thus, the introduction of Cysview is boosting the growth of the market, and it is expected to record a higher growth rate during the forecast period. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.

North America Holds the Largest Market Share

The North American region holds the largest share due to rising R&D activities and well-established healthcare infrastructure in the region. Additionally, the presence of a large number of biologics companies and biopharmaceutical companies is contributing to the large size and excellent growth of the bladder cancer therapeutics and diagnostics market.

North America also has the best adoption rates of new diagnostic modalities that are introduced in the commercial space. This trend is in contrast with other regions of the world, where the most widely adopted technologies for cancer diagnostics are at least a decade old. Consequently, North America is a leader in terms of the market size in the bladder therapeutics and diagnostics market.

Competitive Landscape

The major companies active in the market are AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Novartis, and Pfizer. The companies present in the market are focusing on product innovations, expansions, finding new markets, or innovating their core competencies, in order to expand their market shares.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support